Related Experiment Video
Updated: Oct 13, 2026
Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
Published on: May 7, 2015
Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: an analysis and study using
J D Hosenpud1, S R Pamidi, B S Fiol
1Medical College of Wisconsin,a, Milwaukee, Wisconsin, USA.
Insights
Hepatitis B surface antigenemia (HBsAg) positivity in heart transplant recipients is linked to post-transplant liver disease. While survival may not differ, hepatitis B-related deaths suggest caution for HBsAg+ candidates.
Area of Science:
- Cardiology
- Hepatology
- Transplantation Medicine
Background:
- Hepatitis B surface antigenemia (HBsAg) is a relative contraindication for heart transplantation.
- Liver transplantation is performed for hepatitis B-induced liver disease, but with poorer outcomes.
- The impact of asymptomatic hepatitis B infection on heart transplant outcomes remains unclear.
Purpose of the Study:
- To investigate the impact of pre-transplant hepatitis B surface antigenemia (HBsAg) on heart transplant outcomes.
- To assess the incidence of post-transplant liver disease in HBsAg-positive heart transplant recipients.
Main Methods:
- A cohort of 30 HBsAg-positive patients undergoing heart transplantation was identified from the Joint International Society for Heart and Lung Transplantation/United Network of Organ Sharing Thoracic Registry.
- Data were collected via a 4-question instrument sent to transplant centers.
- Patient outcomes and hepatic status were analyzed.
Main Results:
- The study cohort comprised 30 patients (24 males, 6 females; mean age 46 years).
- Post-transplant, 37% of patients showed evidence of active hepatic inflammation or cirrhosis.
- Hepatitis B-related complications contributed to the majority of deaths (5 out of 9).
Conclusions:
- Hepatitis B surface antigenemia (HBsAg) positive patients often develop post-transplant liver disease, even without pre-existing overt liver disease.
- While no significant survival difference was observed compared to a reference cohort, the high proportion of hepatitis B-related deaths warrants caution.
- These findings suggest careful consideration is needed when evaluating HBsAg-positive candidates for heart transplantation.
Background:
Hepatitis B surface antigenemia (HBsAg) has been considered at least a relative contraindication for heart transplantation, yet patients have undergone liver transplantation for hepatitis B-induced chronic liver disease, albeit with poorer results than for other liver diseases. The impact of asymptomatic hepatitis B infection on heart transplant outcome is not known.
Methods:
To examine this question, we queried the Joint International Society for Heart and Lung Transplantation/United Network of Organ Sharing Thoracic Registry for all patients undergoing heart transplantation who had been identified as positive for HBsAg before transplantation. We then sent a 4-question data instrument to the centers responsible for the identified patients. Seventy-eight patients were identified. Of the 78 data forms sent, 53 forms were returned with the requested data. Of the 53 data forms returned, the centers incorrectly identified 23 patients as positive for HBsAg, resulting in 30 patients who were confirmed as HBsAg positive and who served as the final cohort for this analysis.
Results:
The cohort included 24 males and 6 females, with a mean age of 46 +/- 16 years (range 0 to 68 years). Eleven patients had coronary artery disease, 14 had dilated cardiomyopathy, and 5 patients had a variety of other cardiac diseases. Of those tested at most recent follow-up, 20 of 25 patients continued to be positive for HBsAg, whereas 7 of 21 patients studied had converted and were hepatitis B serum antibody-positive. Approximately 37% of the patients had evidence of active hepatic inflammation or cirrhosis. We found a statistically significant correlation between positivity for hepatitis C antibodies and clinical liver disease (p = 0.0105). No difference in survival could be demonstrated between the study cohort and a reference heart transplant cohort, yet 5 of the 9 deaths were considered to be related to hepatitis B.
Conclusions:
These data demonstrate that clinical liver disease is common post-transplantation in HBsAg+ patients who presumably have no overt liver disease at the time of transplantation. Despite the inability to show a survival difference in this cohort, the fact that the majority of deaths were related to hepatitis B should suggest caution in accepting HBsAg+ patients for cardiac transplantation.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:28Kidney Transplant I: Introduction